Compare KNOP & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KNOP | NGNE |
|---|---|---|
| Founded | 2013 | 2003 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 349.7M | 327.8M |
| IPO Year | 2012 | 2014 |
| Metric | KNOP | NGNE |
|---|---|---|
| Price | $11.04 | $31.90 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | N/A | ★ $63.57 |
| AVG Volume (30 Days) | 81.2K | ★ 170.3K |
| Earning Date | 05-19-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.86% | N/A |
| EPS Growth | N/A | ★ 0.93 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.51 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.00 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.16 | $14.65 |
| 52 Week High | $11.55 | $37.27 |
| Indicator | KNOP | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 60.09 | 70.41 |
| Support Level | $10.04 | $19.40 |
| Resistance Level | N/A | $32.02 |
| Average True Range (ATR) | 0.30 | 2.05 |
| MACD | 0.04 | 0.36 |
| Stochastic Oscillator | 66.85 | 79.36 |
KNOT Offshore Partners LP owns, operates, and shuttles tankers under long-term charters in the North Sea and Brazil. The company provides crude oil loading, transportation, and storage services under time charters and bareboat charters. The Partnership is formed for acquiring ownership interests in over four shuttle tankers owned by Knutsen NYK Offshore Tankers AS (KNOT). It operates through the shuttle tanker market segment.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.